San Diego, CA -- (SBWIRE) -- 11/12/2014 -- An investigation on behalf of investors of Albany Molecular Research, Inc. (NASDAQ:AMRI) shares over potential securities laws violations by Albany Molecular Research and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Albany Molecular Research, Inc. (NASDAQ:AMRI) concerning whether a series of statements by Albany Molecular Research regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Albany Molecular Research, Inc. reported that its annual Total Revenue rose from $198.07 million in 2010 to $246.57 million in 2013 and that its Net Loss of $62.87 million turned into a Net Income of $12.68 million in 2013.
On May 6, 2014, Albany Molecular Research, Inc. announced its first quarter 2014 results. Among other things, Albany Molecular Research said that its first quarter Revenue declined slightly from $59.4 million in 2013 to $59.3 million in 2014 and that its first quarter Net Income declined from $6.5 million in 2013 to $3.5 million in 2014.

On August 5, 2015, Albany Molecular Research, Inc. announced its second quarter 2014 results. Among other, thins Albany Molecular Research, Inc. said that its second quarter Revenue rose from $59.3 million in 2013 to $68.2 million in 2014 and that its second quarter 2013 Net Loss of $2.47 million turned into a second quarter 2014 Net Income of $3.72 million. Albany Molecular Research, Inc. also updated its financial guidance 2014. Among other things, Albany Molecular Research, Inc. said it expects the full year contract revenue guidance increased to between $275 and $283 million, adjusted EBITDA between $59 and $63 million, and adjusted diluted EPS range between $0.87 and $0.92, compared to $0.70 in 2013.

Shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) grew from $2.21 per share in late 2011 to as high as $23.85 per share on November 3, 2014.

Then on November 5, 2014, Albany Molecular Research, Inc. announced its third quarter 2014 results. Albany Molecular Research, Inc reported that its third quarter Revenue rose from $60.75 million in 2013 to $62.47 million in 2014, while its third quarter 2013 Net Income of $3.7 million declined to a third quarter 2014 Net Loss of $8.64 million.

Among other things, Albany Molecular Research, Inc also adjusted its financial outlook for the fully year 2014. Albany Molecular Research, Inc said it now expects full year contract revenue is expected to be between $253 and $261 million, adjusted EBITDA between $50 and $52 million, and adjusted diluted EPS is expected to be between $0.67 and $0.73.

Shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) declined to as low as $14.83 per share during November 6, 2014.

On November 10, 2014, NASDAQ:AMRI shares closed at $17.10 per share.

Those who purchased shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com